Review anchor
Prostaglandin G/H synthase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Prostaglandin G/H synthase 2
CHEMBL230
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Prostaglandin G/H synthase 2 as ChEMBL target CHEMBL230, mapped to UniProt P35354. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL230
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P35354
Prostaglandin G/H synthase 2
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Prostaglandin G/H synthase 2 matters
Prostaglandin G/H synthase 2 is reviewed as Prostaglandin G/H synthase 2 (UniProt P35354); Prostaglandin G/H synthase 2 shows approved-linked disease relevance led by osteoarthritis. 5 more disease programs remain visible in the same review block.; 11 linked drugs keep this evidence frame grounded.; the current evidence base includes 50 approved drugs, 8961 compounds, and 1318 assays, with lead potency reaching pChEMBL 10.7.
Protein context
Prostaglandin G/H synthase 2
Prostaglandin G/H synthase 2 Sequence length is 604 aa.
Review this target as Prostaglandin G/H synthase 2, mapped to UniProt P35354. Sequence length is 604 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P35354
Protein
Disease context
osteoarthritis
Prostaglandin G/H synthase 2 shows approved-linked disease relevance led by osteoarthritis. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ACECLOFENAC, CELECOXIB, ETODOLAC.
Start review with osteoarthritis because it currently carries approved-linked support. Linked drugs include ACECLOFENAC, CELECOXIB, ETODOLAC, ETORICOXIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
11 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 50 approved drugs, 8961 compounds, and 1318 assays for this target. The dominant activity type is IC50. CHEMBL499069 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL499069 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
50 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Prostaglandin G/H synthase 2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P35354, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why osteoarthritis is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
8961
Total Compounds
1318
Total Assays
50
Approved Drugs
IC50: 8346.0, KI: 863.0, EC50: 2.0, KD: 8.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL499069
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL501208
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL525247
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL502555
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL143776
|
10.1 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ESFLURBIPROFEN
CHEMBL435298
|
2015 |
|
|
VORTIOXETINE
CHEMBL2104993
|
2013 |
|
|
LUMIRACOXIB
CHEMBL404108
|
2005 |
|
|
ETORICOXIB
CHEMBL416146
|
2002 |
|
|
PARECOXIB
CHEMBL1206690
|
2002 |
|
|
VALDECOXIB
CHEMBL865
|
2001 |
|
|
MELOXICAM
CHEMBL599
|
2000 |
|
|
ROFECOXIB
CHEMBL122
|
1999 |
|
|
CELECOXIB
CHEMBL118
|
1998 |
|
|
BROMFENAC
CHEMBL1077
|
1997 |
|
|
DEXIBUPROFEN
CHEMBL175
|
1994 |
|
|
MOFEZOLAC
CHEMBL259972
|
1994 |
|
|
DEXKETOPROFEN
CHEMBL75435
|
1994 |
|
|
OXAPROZIN
CHEMBL1071
|
1992 |
|
|
ETODOLAC
CHEMBL622
|
1991 |
|
|
KETOROLAC
CHEMBL469
|
1989 |
|
|
KETOROLAC TROMETHAMINE
CHEMBL1201124
|
1989 |
|
|
DICLOFENAC
CHEMBL139
|
1988 |
|
|
DICLOFENAC SODIUM
CHEMBL1034
|
1988 |
|
|
CARPROFEN
CHEMBL1316
|
1987 |
|
|
KETOPROFEN
CHEMBL571
|
1986 |
|
|
FLURBIPROFEN
CHEMBL563
|
1986 |
|
|
MECLOFENAMIC ACID
CHEMBL509
|
1980 |
|
|
MECLOFENAMATE SODIUM
CHEMBL1562610
|
1980 |
|
|
TOLMETIN
CHEMBL1020
|
1976 |
|
|
NAPROXEN
CHEMBL154
|
1976 |
|
|
IBUPROFEN
CHEMBL521
|
1974 |
|
|
MEFENAMIC ACID
CHEMBL686
|
1967 |
|
|
INDOMETHACIN
CHEMBL6
|
1965 |
|
|
HEXACHLOROPHENE
CHEMBL496
|
1949 |
|
|
NIMESULIDE
CHEMBL56367
|
— |
|
|
3,3',4',5-TETRACHLOROSALICYLANILIDE
CHEMBL291338
|
— |
|
|
NITROXOLINE
CHEMBL1454910
|
— |
Source Header